# Takeda

Source: https://onco.cc/companies/takeda/  
OnCo record `takeda` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Takeda co-owns Adcetris outside the US and is developing STING-agonist conjugates and CAR-NK cells.

## Summary

Takeda, based in Tokyo and listed as 4502.T, co-owns Adcetris, or brentuximab vedotin, outside the United States and is developing STING-agonist antibody conjugates and cord-blood CAR-NK cells with MD Anderson. Its oncology portfolio also includes bortezomib, brigatinib, fruquintinib and anagrelide, while mobocertinib was withdrawn, and TAK-500 is its STING immune-stimulating antibody conjugate. OnCo links it to the ECHELON-1 paper, in which brentuximab vedotin replaced bleomycin in first-line Hodgkin lymphoma chemotherapy, to Hutchmed and Innovent as partners, and to Takeda Ventures. Whether off-the-shelf CAR-NK cells can match autologous CAR-T on durability is the open question behind its MD Anderson collaboration. Brentuximab vedotin has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Millennium Pharmaceuticals; Ariad Pharmaceuticals; ARIAD; Nycomed; Shire
- HQ: Tokyo
- Type: pharma
- Website: https://www.takeda.com
- Ticker: 4502.T

## Sources

- Official website: https://www.takeda.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Anagrelide](https://onco.cc/drugs/anagrelide/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Brigatinib](https://onco.cc/drugs/brigatinib/), [Elritercept](https://onco.cc/drugs/elritercept/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Human normal immunoglobulin (IVIg)](https://onco.cc/drugs/human-normal-immunoglobulin/), [Ixazomib](https://onco.cc/drugs/ixazomib/), [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/), [Mifamurtide](https://onco.cc/drugs/mifamurtide/), [Mobocertinib](https://onco.cc/drugs/mobocertinib/), [Orteronel](https://onco.cc/drugs/orteronel/), [Pevonedistat](https://onco.cc/drugs/pevonedistat/), [Ponatinib](https://onco.cc/drugs/ponatinib/), [Rusfertide](https://onco.cc/drugs/rusfertide/), [Sapanisertib](https://onco.cc/drugs/sapanisertib/), [Serabelisib](https://onco.cc/drugs/serabelisib/), [TAK-928](https://onco.cc/drugs/tak-928/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/), [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/), [Hutchmed](https://onco.cc/companies/hutchmed/), [Innovent Biologics](https://onco.cc/companies/innovent/), [Protagonist Therapeutics](https://onco.cc/companies/protagonist-therapeutics/), [Takeda Ventures](https://onco.cc/companies/takeda-ventures/)
- trials: [A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07217301/), [A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma](https://onco.cc/trials/nct02979522/), [A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)](https://onco.cc/trials/nct05673785/), [A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B](https://onco.cc/trials/nct06499285/), [A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma](https://onco.cc/trials/nct06980480/), [A Study of Rusfertide in Japanese Adults With Polycythemia Vera](https://onco.cc/trials/nct07648030/), [A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)](https://onco.cc/trials/nct05020015/), [A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors](https://onco.cc/trials/nct07205718/), [A Study of TAK-505 in Adults With Solid Tumors](https://onco.cc/trials/nct07436728/), [A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct02716116/), [A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors](https://onco.cc/trials/nct06390995/), [ALCANZA](https://onco.cc/trials/alcanza/), [ALTA](https://onco.cc/trials/alta/), [ALTA-1L](https://onco.cc/trials/alta-1l/), [ECHELON-1](https://onco.cc/trials/echelon-1/), [ECHELON-2](https://onco.cc/trials/echelon-2/), [ELM-PC 4](https://onco.cc/trials/elm-pc-4-orteronel/), [FRESCO-2](https://onco.cc/trials/fresco-2/), [INTUITT-NF2](https://onco.cc/trials/intuitt-nf2/), [PARADIGM](https://onco.cc/trials/paradigm/), [Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)](https://onco.cc/trials/nct03268954/), [PhALLCON](https://onco.cc/trials/phallcon/), [TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct04129502/), [VERIFY](https://onco.cc/trials/verify/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- key papers: [Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)](https://onco.cc/key-papers/paper-alta-jco-2017/), [ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/takeda.json